Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for <1 year. The efficacy/effectiveness of these treat­ments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Sev...

Full description

Bibliographic Details
Main Authors: Lieneke F.M. Ariëns, Abhijit Gadkari, Harmieke van Os-Medendorp, Rajeev Ayyagari, Emi Terasawa, Andreas Kuznik, Zhen Chen, Gaëlle Bégo-Le Bagousse, Yufang Lu, Elena Rizova, Neil M.H. Graham, Gianluca Pirozzi, Marjolein De Bruin-Weller, Laurent Eckert
Format: Article
Language:English
Published: Medical Journals Sweden 2019-06-01
Series:Acta Dermato-Venereologica
Subjects:
adult
atopic dermatitis
cyclosporine
dupilumab
Eczema Area and Severity Index
eczema
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3219

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3219

Similar Items